Cell surface antigen modification is a recognized mechanism of immune evasion and therapeutic resistance, and it raises concerns that CD5 downregulation may impact the success of CD5-targeted therapies in CTCL. This evidence concerns the gene CD5 and primary cutaneous T-cell non-Hodgkin lymphoma.